This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …

This meta-analysis was conducted with the aim to assess the safety and efficacy of
favipiravir in treating patients with coronavirus disease 2019 (COVID-19). It was carried out …

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …

Interim phase III trial results, released through a press release by the drug's manufacturer,
MSD, found that molnupiravir reduced the risk of admission to hospital or death by around …

Twonewantiviralmedications, ritonavir-boostednirmatrelvir (Paxlovid, ie, nirmatrelvir-
ritonavir) and molnupiravir (Lagevrio), are currently availableintheUSunderemergencyuseautho …

Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐
hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and …

Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …